
Abeona Therapeutics Inc.
NASDAQ:ABEO
Overview | Financials
Company Name | Abeona Therapeutics Inc. |
Symbol | ABEO |
Currency | USD |
Price | 5.49 |
Market Cap | 267,911,451 |
Dividend Yield | 0% |
52-week-range | 3.93 - 7.32 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Vishwas Seshadri M.B.A., Ph.D. |
Website | https://www.abeonatherapeutics.com |
An error occurred while fetching data.
About Abeona Therapeutics Inc.
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD